CARsgen’s CT053 has been developed to deal with relapsed/refractory a number of myeloma. Credit score: Nephron / Wikimedia. CARsgen Therapeutics has introduced a collaboration with Huadong Medication to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. The totally human, autologous BCMA CAR T-cell product candidate of CARsgen, CT053 has been developed to deal with relapsed/refractory […]